Efficacy of upfront hepatectomy without neoadjuvant chemotherapy for resectable colorectal liver metastasis

BackgroundHepatectomy for resectable colorectal liver metastasis (CRLM) is recommended. However, the efficacy of upfront hepatectomy without neoadjuvant chemotherapy (NAC) is unclear due to the uncertainty of perioperative systemic chemotherapy. Moreover, it is crucial to predict the prognosis when considering perioperative chemotherapy. This study evaluated the impact of neoadjuvant chemotherapy on the prognosis of patients with resectable CRLM and assessed the usefulness of Beppu's nomogram for predicting prognosis.MethodsThis retrospective study identified 88 consecutive inpatients who underwent primary hepatic resection for CRLM; 58 received neoadjuvant chemotherapy and 30 underwent upfront surgery. Factors associated with recurrence-free survival were identified via univariate and multivariate analysis. Furthermore, propensity score analysis using inverse probability of treatment weighting (IPTW) was performed.ResultsOn univariate analysis, poor recurrence-free survival was associated with multiple tumors, advanced primary tumor stage, vascular invasion by the primary tumor, a Beppu's nomogram score >= 6, and neoadjuvant chemotherapy. On multivariate analysis, a Beppu's nomogram score >= 6 and neoadjuvant chemotherapy were independent risk factors for recurrence. Neoadjuvant chemotherapy recipients had a higher incidence of lymph node metastasis and vascular invasion than non-recipients. Propensity score analysis revealed no significant difference in the recurrence-free survival rate between these groups.ConclusionsOur results show that upfront hepatectomy without neoadjuvant chemotherapy can be considered for resectable CRLM treatment. Beppu's nomogram score can be a tool for predicting the prognosis of patients with CRLM.

Automated summary

Our study revealed that neoadjuvant chemotherapy and Beppu's nomogram score are independent risk factors for recurrence in patients with resectable CRLM. Upfront hepatectomy without neoadjuvant chemotherapy can be considered for treating resectable CRLM. Recipients of neoadjuvant chemotherapy had higher incidence of lymph node metastasis and vascular invasion compared to non-recipients.